Neurologic aspects of adenylosuccinate lyase deficiency.
Adenylosuccinate lyase deficiency is an autosomal-recessive disorder of the purine de novo synthesis pathway, diagnosed up to now in approximately 40 patients. The clinical presentation is characterized by severe neurologic involvement including seizures, developmental delay, hypotonia, and autistic features. Neonatal seizures and a severe infantile epileptic encephalopathy are often the first manifestations of this disorder. The existence of genetic heterogeneity for the adenylosuccinate lyase defect could account for variability of the clinical presentation. Deficiency of purine nucleotides, impairment of energy metabolism, and toxic effects are potential mechanisms of cerebral damage. Laboratory investigations show the presence in urine and cerebrospinal fluid of succinylpurines, which are normally undetectable. Currently, no effective treatment is available for adenylosuccinate lyase deficiency. A search for this disorder should be included in the screening program of children with unexplained neonatal seizures or severe infantile epileptic encephalopathy.
Ciardo
F
F
Department of Neuroscience, Tor Vergata University of Rome, Italy.
Salerno
C
C
Curatolo
P
P
D000264:Adenylosuccinate Lyase / Q000172:deficiency* / Q000235:genetics*; D001921:Brain / Q000201:enzymology*; D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000378:metabolism; D004734:Energy Metabolism / Q000502:physiology; D004827:Epilepsy / Q000378:metabolism; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011685:Purine Nucleotides / Q000652:urine
D011685:Purine Nucleotides; D000264:Adenylosuccinate Lyase